EntreMed cancer drug deemed safe
The review was undertaken to assess the safety of the drug, MKC-1 in a phase II trial in patients with advanced or metastatic breast cancer who have failed
The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) from Pfizer and Valneva for their Lyme disease vaccine candidate, PF-07307405.